New studies into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are demonstrating encouraging results in treating excess mass and related second-type condition. Initial data suggest a unique process https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/